| 货号 | 2956/10 |
| 别名 | (5R,5aS,8aR,9R)-5,8,8a,9-Tetrahydro |
| 是否允许进口 | 否 |
| 是否危险品 | 是 |
| 供应商 | Tocris |
| 生物活性 | Orally active insulin-like growth factor 1 receptor (IGF1R) inhibitor that exhibits no activity at the insulin receptor, FGFR, PDGFR or EGFR. Inhibits IGF1R autophosphorylation (IC50 ~ 1 nM), increases the fraction of cells in the G2/M phase and upregulates apoptosis. Exhibits antiproliferative effects in multiple cancer cell lines (IC50 = 0.05 - 15 μM), and has anticancer and antineovascularization activity in vivo. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 纯度 | >97 % |
| 计算分子量 | 414.41 |
| 分子式 | C22H22O8 |
| 可溶性/溶解性 | Soluble to 100 mM in DMSO |
| 参考文献 | Economouet al (2008) Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. Invest.Ophthalmol.Vis.Sci. 49 2620. PMID: 18515591. Stromberget al (2006) IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 107 669. PMID: 16166596. Girnitaet al (2004) Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 64 236. PMID: 14729630. |